Open Access

Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)

  • Authors:
    • Tong Zhang
    • Di Yang
    • Liang Tang
    • Yu Hu
  • View Affiliations

  • Published online on: June 26, 2024     https://doi.org/10.3892/mmr.2024.13272
  • Article Number: 148
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The coronavirus disease 2019 pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) seriously affected global public health security. Studies on vaccines, neutralizing antibodies (NAbs) and small molecule antiviral drugs are currently ongoing. In particular, NAbs have emerged as promising therapeutic agents due to their well‑defined mechanism, high specificity, superior safety profile, ease of large‑scale production and simultaneous application for both prevention and treatment of viral infection. Numerous NAb therapeutics have entered the clinical research stages, demonstrating promising therapeutic and preventive effects. These agents have been used for outbreak prevention and control under urgent authorization processes. The present review summarizes the molecular targets of SARS‑CoV‑2‑associated NAbs and screening and identification techniques for NAb development. Moreover, the current shortcomings and challenges that persist with the use of NAbs are discussed. The aim of the present review is to offer a reference for the development of NAbs for any future emergent infectious diseases, including SARS‑CoV‑2.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 30 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang T, Yang D, Tang L and Hu Y: Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Mol Med Rep 30: 148, 2024.
APA
Zhang, T., Yang, D., Tang, L., & Hu, Y. (2024). Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Molecular Medicine Reports, 30, 148. https://doi.org/10.3892/mmr.2024.13272
MLA
Zhang, T., Yang, D., Tang, L., Hu, Y."Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)". Molecular Medicine Reports 30.2 (2024): 148.
Chicago
Zhang, T., Yang, D., Tang, L., Hu, Y."Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)". Molecular Medicine Reports 30, no. 2 (2024): 148. https://doi.org/10.3892/mmr.2024.13272